Evidence map›Paper›PMID 26453792›Full record

ArticleBone2016

The effects of maternal iron deficiency on infant fibroblast growth factor-23 and mineral metabolism.

V S Braithwaite, A Prentice, M K Darboe, A M Prentice, S E Moore

Open access · hybridAbstract read
In one paragraph

Article in Bone, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Developmental Changes in Phosphate Homeostasis.Reviews of physiology, biochemistry and pharmacology · 2021
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

V S BraithwaiteMRC Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge CB1 9NL, UK and MRC Unit, The Gambia. Electronic address: vickie.braithwaite@mrc-hnr.cam.ac.uk.
A PrenticeMRC Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge CB1 9NL, UK and MRC Unit, The Gambia.
M K DarboeMRC International Nutrition Group at London School of Hygiene & Tropical Medicine, Keppel St, London WC1E 7HT, UK and MRC Unit, The Gambia.
A M PrenticeMRC International Nutrition Group at London School of Hygiene & Tropical Medicine, Keppel St, London WC1E 7HT, UK and MRC Unit, The Gambia.
S E MooreMRC Human Nutrition Research, Elsie Widdowson Laboratory, Fulbourn Road, Cambridge CB1 9NL, UK and MRC Unit, The Gambia; MRC International Nutrition Group at London School of Hygiene & Tropical Medicine, Keppel St, London WC1E 7HT, UK and MRC Unit, The Gambia.
London School of Hygiene & Tropical Medicine · GBMRC Human Nutrition Research · GB

Funding

Medical Research Council MCA760-5QX00Medical Research Council MC_U123292699Medical Research Council MC_U123292701Medical Research Council MC_UP_1005/1Medical Research Council MR/P012019/1Medical Research Council U105960371Medical Research Council U123261351
6 · The paper itself

Abstract

Fibroblast growth factor-23 (FGF23), a phosphate(Phos)-regulating hormone, is abnormally elevated in hypophosphataemic syndromes and an elevated FGF23 is a predictor of mortality in kidney disease. Recent findings suggest iron deficiency as a potential mediator of FGF23 expression and murine studies have shown in utero effects of maternal iron deficiency on offspring FGF23 and phosphate metabolism. Our aim was to investigate the impact of maternal iron status on infant FGF23 and mineral metabolites over the first 2years of life. Infants born to mothers with normal (NIn=25,) and low (LIn=25) iron status during pregnancy, from a mother-infant trial (ISRCTN49285450) in rural Gambia, West Africa, had blood and plasma samples analysed at 12, 24, 52, 78 and 104weeks (wk) of age. Circulating intact-FGF23 (I-FGF23), Phos, total alkaline phosphatase (TALP) and haemoglobin (Hb) decreased and estimated glomerular filtration rate increased over time [all P≤0.0001)]. C-terminal-FGF23 (C-FGF23) and TALP were significantly higher in LI compared with NI, from 52wk for C-FGF23 [Beta coefficient (SE) 18.1 (0.04) %, P=0.04] and from 24wk for TALP [44.7 (29.6) U/L, P=0.04]. Infant Hb was the strongest negative predictor of C-FGF23 concentration [-21% (4%) RU/mL, P≤0.0001], Phos was the strongest positive predictor of I-FGF23 [32.0(3.9) pg/mL, P≤0.0001] and I-FGF23 did not predict C-FGF23 over time [-0.5% (0.5%), P=0.3]. In conclusion, this study suggests that poor maternal iron status is associated with a higher infant C-FGF23 and TALP but similar I-FGF23 concentrations in infants and young children. These findings further highlight the likely public health importance of preventing iron deficiency during pregnancy. Whether or not children who are born to iron deficient mothers have persistently high concentrations of these metabolites and are more likely to be at risk of impaired bone development and pre-disposed to rickets requires further research.

Indexed as

AnemiaAnthropometryBiomarkersChildChild, PreschoolFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHemoglobinsHumansInfantIronMineralsPregnancyTime FactorsBiomarkersFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsHemoglobinsIronMineralsAfricaBone healthEarly lifeFGF23Iron status in pregnancyPhosphate

Identifiers

PMID26453792
PMCPMC4720219
OpenAlexW2138968761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.